Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development
Joint Authors
Lipinska, Danuta
Milewski, Robert
Popławska-Kita, Anna
Szelachowska, Małgorzata
Wawrusewicz-Kurylonek, Natalia
Siewko, Katarzyna
Maciulewski, Rafal
Zielinska-Maciulewska, Anna
Szumowski, Piotr
Górska, Maria
Kretowski, Adam
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-7, 7 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-10-20
Country of Publication
Egypt
No. of Pages
7
Main Subjects
Abstract EN
Aim.
The aim of our study was to assay circulating interleukin-15 (IL-15) and interleukin-6 (IL-6) levels and insulin resistance measured by two different methods in newly diagnosed autoimmune diabetes (AD) patients, their I° relatives, and healthy controls.
Material and Methods.
The group studied consisted of 54 patients with AD (28 with Latent Autoimmune Diabetes in Adults (LADA) and 26 with type 1 diabetes (T1D)), 70 first-degree relatives, and 60 controls.
IL-6, IL-15, and anti-islet antibodies concentrations were measured by ELISA method.
Homeostatic model assessment-insulin resistance (HOMAIR) and estimated glucose disposal rate (eGDR) were calculated.
Results.
The patients with AD had significantly higher IL-15, IL-6, and HOMAIR and lower eGDR than the controls (p<0.001, respectively) and first-degree relatives (p<0.001, respectively).
Significantly higher IL-15 and IL-6 were shown in the relatives with positive Ab as compared to the relatives without antibodies (p<0.001, respectively) and the controls (p<0.001, respectively).
IL-15 negatively correlated with eGDR (r=−0.436, p=0.021) in LADA and positively with HOMAIR in LADA and T1D (r=0.507, p<0.001; r=0.4209, p<0.001).
Conclusions.
Significantly higher IL-15 and IL-6 concentrations, HOMAIR, and markedly lower eGDR in newly diagnosed AD patients and first-degree relatives with positive anti-islet antibodies might suggest the role of these pro-inflammatory cytokines and insulin resistance in the pathogenesis of autoimmune diabetes.
IL-15 and IL-6 might be used as biomarkers of the risk of autoimmune diabetes development, in particular IL-15 for LADA.
Both methods of IR measurement appear equally useful for calculating insulin resistance in autoimmune diabetes.
American Psychological Association (APA)
Siewko, Katarzyna& Maciulewski, Rafal& Zielinska-Maciulewska, Anna& Popławska-Kita, Anna& Szumowski, Piotr& Wawrusewicz-Kurylonek, Natalia…[et al.]. 2019. Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development. BioMed Research International،Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1125548
Modern Language Association (MLA)
Siewko, Katarzyna…[et al.]. Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development. BioMed Research International No. 2019 (2019), pp.1-7.
https://search.emarefa.net/detail/BIM-1125548
American Medical Association (AMA)
Siewko, Katarzyna& Maciulewski, Rafal& Zielinska-Maciulewska, Anna& Popławska-Kita, Anna& Szumowski, Piotr& Wawrusewicz-Kurylonek, Natalia…[et al.]. Interleukin-6 and Interleukin-15 as Possible Biomarkers of the Risk of Autoimmune Diabetes Development. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1125548
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1125548